Quote · Pivot
Starmer Resigns, Reflecting Pool Fiasco, and Amazon Dumps OpenAI Movie
Where this was said
GLP-1 Drugs: The Innovation With Only Good News
At 50:46 · chapter starts 48:00
The GLP-1 conversation starts as an aside about SpaceX shorts and longs — Scott says if he had to go long any category it would be GLP-1s — and quickly becomes one of the episode's most substantive health segments. New findings from the American Clinical Oncology gathering show that metastatic cancer growth rates are cut in half in patients on GLP-1s. Potential delays in dementia and Alzheimer's are also being studied. Kara discloses that her cardiologist has already recommended a low dose for her after her stroke. Scott notes that every new GLP-1 study comes back with positive news — which is almost unprecedented for any major medical innovation. Externalities are usually negative (chemo causes leukemia, Big Tech causes polarisation), but GLP-1s keep surprising researchers. Both hosts predict the drug will move from 1 in 8 Americans to eventually 1 in 2, citing shifts in food consumption toward proteins and the market disruption for snack brands.
Every new study on GLP-1 drugs comes back positive. Data from the American Clinical Oncology gathering shows metastatic cancer growth rates are cut in half for patients on GLP-1s. Scott Galloway predicts 1 in 2 Americans will eventually be on some form of the drug.
New findings from the American Clinical Oncology gathering suggest GLP-1 drugs cut the growth rates of metastatic cancers in half, adding to a growing list of positive second-order effects.
Approximately one in eight Americans is currently taking a GLP-1 drug, with Scott Galloway predicting that figure could eventually reach one in two.
